Table 3.

Drug susceptibility test of Mycobacterium simiae in different geographical areas and treatment regimens of pulmonary infection M. simiae.

	Number of patients	Susceptibility tests	Treatment	Outcome
Hamieh, 2018 [9]Lebanon	51	Susceptible to: (88%) AMK, (19%) SMX‐TMP, and (30%) MOX, two of the isolates that were resistant to all the tested antibiotics, except CLR, were tested against CLO and found to be susceptible	CLR, SMX‐TMP or MOX. CLR with CLO was used in two patients	Six to 24 months. Four patients noted improvement. Two patients received a combination of CLO and CLR improvement
Coolen‐Allou, 2018 [10] France	97	Susceptible to: AMK, MOX, CIP, and CLR Resistant to: R, E, and H	CLR, E, MOX, CLO, and AMK	Treatment failure in two patients, other patient found no relapse with M. simiae
Cowman, 2016 [11] United Kingdom	55 Retrospective study	Susceptible to: CLO, CYC, and AMK Resistant to: H, E, RB, Ri, STR, and CLR	—	—
Baghaei, 2012 [12] Iran	26	Resistant to: H, R, E, Z, and STR	CLR, OFX, and SMX‐TMP	12 months, 24 patients were cured and two patients failed the treatment
Van Ingen, 2008 [13] The Netherlands	6	Susceptible to: CLO, CYC, and (76%) PRO Resistant to: Ri, E, H, STR, AMK, CIP (72%), and CLR (84%)	R, E, CIP, and CLR	One of them was cured, one relapsed, and one died
This study 2020	1	Susceptible to: CLO and AMK Resistant to: STR, CLR, SMX‐TMP, and MOX	LVX, CLR, and SMX‐TMP	Death

AMK, amikacin; CIP, ciprofloxacin; CLO, clofazimine; CLR, clarithromycin; CYC, cycloserine; E, ethambutol; H, isoniazid; LVX, levofloxacin; MOX, moxifloxacin; OFX, ofloxacin; PRO, protionamide; R, rifampin; RB, rifabutin; Ri, rifampicin; SMX‐TMP, cotrimoxazole; STR, streptomycin; Z, pyrazinamide.